Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By
Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer. 1,2 It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World.1 The current standard of care is intensive chemotherapy, but many older patients cannot tolerate this therapeutic approach; their…

















